1818 Market Street, Suite 2350, Suite 2350
16 articles with Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Pharmaceuticals and one abstract from an investigator-sponsored trial will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies, known as "SLEEP," in San Antonio from June 8-12, 2019.
Jazz Pharmaceuticals plc announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA.
Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Poten...
5/11/2018Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney's Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.
Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting
Twenty abstracts including eight oral presentations to showcase Jazz's breadth and depth of sleep medicine innovation [10-May-2018] Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting Twenty abstracts including eight oral pre
Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) on April 27, 2018 seeking revised labeling for Xyrem® (sodium oxybate) oral solution, CIII, to include an indication to treat cataplexy and EDS in pediatric narcolepsy patients.
Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development.
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard review the company's New Drug Application (NDA) seeking marketing approval for solriamfetol, an investigational medicine for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety of defibrotide for the prevention of acute Graft-versus-Host-Disease (aGvHD) in adult and pediatric patients after allogeneic hematopoietic stem cell transplant (HSCT).
Jazz Pharma today announced that it will report its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018, after the close of the financial markets.
National Comprehensive Cancer Network adds Jazz Pharma's Vyxeos Liposome for Injection to Clinical Practice Guidelines in Oncology
Vyxeos is the first FDA-approved treatment specifically for adults with newly-diagnosed Therapy-Related AML or AML with AML-MRC.
Jazz Pharma Submits NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated With Narcolepsy and Obstructive Sleep Apnea
Jazz Pharma today announced the submission of a NDA to the FDA on December 20, 2017.
Jazz Pharmatoday announced the appointment of Daniel N. Swisher, Jr. as president and COO, effective January 3, 2018.
Pfenex Reports Third Quarter 2017 Results, Interim PK Data From PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update
Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars.
GAAP net income for the third quarter of 2017 was $63.5M, or $1.03 per diluted share, compared to $89.8M, or $1.45 per diluted share, for the third quarter of 2016.
Jazz Pharma Submits Vyxeos Marketing Authorization Application to EMA for Treatment of Certain Types of High-Risk AML
The CHMP granted Vyxeos accelerated assessment, which is designed to reduce the review timeline for products of major interest for public health and therapeutic innovation.
Jazz Pharma today announced that it will report its 2017 third quarter financial results on Tuesday, November 7, 2017, after the close of the financial markets.